The study is about finding out if the combination of two medicines, pasritamig and docetaxel, helps men with advanced prostate cancer live longer without their disease getting worse, compared to using just docetaxel. Prostate cancer is a disease where bad cells grow in the prostate gland, which is under the bladder in men.

Participants must have a confirmed prostate cancer that has spread to other parts of the body. They need to continue hormone therapy or have had surgery to remove testicles, ensuring low testosterone levels. They must have tried but not used more than two different hormone therapies.

• Study Duration: The duration isn't specified, but participants will receive treatments and regular scans.
• Visits Required: Regular visits for treatment and scans will be necessary.
• Risks: Participants should be aware of potential side effects from the drugs used in the study.